STOCK TITAN
  1. Home
  2. News
  3. IXHL

Incannex Healthcare Inc - ixhl STOCK NEWS

Welcome to our dedicated news page for Incannex Healthcare (Ticker: ixhl), a resource for investors and traders seeking the latest updates and insights on Incannex Healthcare.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Incannex Healthcare's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Incannex Healthcare's position in the market.

News
Federal Court of Australia Approves Incannex’s Re-Domiciliation and Lodgement of Court Orders With ASIC
Rhea-AI Summary
Incannex Healthcare Limited (ASX: IHL) (NASDAQ: IXHL) announces the approval of the scheme of arrangement for the proposed re-domiciliation from Australia to the United States. The Federal Court of Australia has made orders approving the scheme, with Incannex Healthcare Inc. becoming the ultimate parent company. The company has applied to suspend quotation and trading of shares on ASX, with ADRs continuing to trade on Nasdaq until the implementation date. Shareholders and optionholders will be entitled to receive the Scheme consideration on the implementation date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.28%
Tags
none
-
News
Incannex Announces Participation at the H.C. Wainwright 25th Annual Global Investment Conference - September 11-13, 2023
Rhea-AI Summary
Incannex to present at H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.56%
Tags
none
-
News
Incannex to Prepare FDA IND Application for Psilocybin-assisted Psychedelic Psychotherapy Program, Known as Psi-GAD
Rhea-AI Summary
Incannex Healthcare prepares IND application for psilocybin therapy, positive interim analysis predicts significant benefit in Phase 2 trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.26%
Tags
clinical trial
News
Review of IND Application for IHL-42X by US FDA has been completed; Clinical Trial for Patients with Obstructive Sleep Apnoea May Proceed
Rhea-AI Summary
Incannex receives FDA approval for IND opening pivotal IHL-42X Phase 2/3 clinical trial in the United States.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.33%
Tags
clinical trial
-
News
Clarion Clinics Begins Accepting Registrations for Psychedelic Treatment Interest as Part of Pre-Screening in Readiness for Opening
Rhea-AI Summary
Incannex subsidiary, Clarion Clinics Group, is now accepting registrations of interest for its psychedelic-assisted therapy treatments. The first clinic in Melbourne is nearing completion and will offer a nine-month treatment program. Treatments will begin after final approval from the Therapeutic Goods Administration. Health authorities estimate that 390,000 Australians suffer from PTSD and 280,000 suffer from treatment-resistant depression.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.72%
Tags
none
-
News
Incannex Healthcare June 2023 Quarterly Activities Report and Appendix 4C Cash Flow Statement
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.12%
Tags
none
News
Incannex Completes Positive Pre-IND Meeting with US FDA on IHL-675A for Treatment of Rheumatoid Arthritis
Rhea-AI Summary
Incannex Healthcare Limited has completed a pre-IND meeting with the FDA for its drug product IHL-675A, designed for the treatment of rheumatoid arthritis. The FDA provided valuable feedback and confirmed that no further nonclinical studies are needed for the IND application. They also provided guidance on the requirements for submitting a New Drug Application via the 505(b)(2) pathway.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.74%
Tags
none
-
News
Incannex Submits IND Application to the US FDA for IHL-42X for Obstructive Sleep Apnoea
Rhea-AI Summary
Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL) has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for IHL-42X, a treatment for obstructive sleep apnoea. The application includes safety and efficacy data, clinical trial protocol, and investigator information. The company aims to conduct a multi-site phase 2/3 clinical trial to assess IHL-42X in patients with OSA who are intolerant, non-compliant, or naïve to positive airway pressure. The trial will compare IHL-42X, dronabinol, acetazolamide, and placebo over a 52-week treatment period. Two experienced research clinicians have been appointed as Principal Investigators for the trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.51%
Tags
clinical trial
-
News
Incannex engages Fortrea to Manage its FDA IND Opening Phase 2/3 Clinical Trial Investigating IHL-42X for Treatment of Obstructive Sleep Apnoea
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.65%
Tags
clinical trial
News
Incannex Receives HREC Approval for Phase 2 Clinical Trial Assessing IHL-675A for use in Treatment of Pain and Function in Rheumatoid Arthritis
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.02%
Tags
clinical trial
Stock IXHL logo
Incannex Healthcare Inc

Nasdaq:IXHL

IXHL Rankings

#4899 Ranked by Market Cap
#5228 Ranked by Stock Gains
N/A Ranked by Dividends

IXHL Stock Data

47.29M
12.79M
21.54%
6.39%
0.56%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
Australia
Sydney